|
|
|
Abilify information Brazil
|
Aripiprazole (ay-ree-PIP-ray-zole) (sold as Abilify) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, as well as treatment of depression. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.
Advertised brand: Abilify - Bristol Myers Squibb
Advert title(s): Campaign (Visual Aid, Sales Aid, Notebook, Leaflets, Scientific Information, Product Information, Slim Jim)
Translation of headline to English: N/A
Advertising Agency (Name, City, Country): Ogiva Propaganda Ilimitada - São Paulo - Brazil
Agency website: http://www.ogiva.com.br
Creative Director: Erick Cedric
Art Director: Luiz Silveira / Fabio Gallo
Copywriter: Marcia Trommer
Published/Released: 2005/2006
|
|
| Rate this file (No vote yet) |
|
|
|
|
|
|
